Cannabis Public Health: Peer-Reviewed Research Consensus

38 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis public health includes 38 peer-reviewed studies spanning 2025–2026. Of these, 6 provide strong evidence, including 0 meta-analyses and 0 randomized controlled trials. Key findings with strong support include: meta-analysis of 220,362 adolescents across 47 countries found 7% global cannabis prevalence, with boys and high-income countries showing higher rates and latin america leading regionally, and 20-year analysis of german addiction treatment data found cannabis-related admissions nearly tripled (7. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

Meta-analysis of 220,362 adolescents across 47 countries found 7% global cannabis prevalence, with boys and high-income countries showing higher rates and Latin America leading regionally

Moderate Evidence
6 studies|Based on limited number of strong-evidence studies.

20-year analysis of German addiction treatment data found cannabis-related admissions nearly tripled (7

Moderate Evidence
6 studies|Based on limited number of strong-evidence studies.

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

National case-control study found cannabis use associated with 83% increased odds of suicide death, independent of alcohol

Moderate Evidence
10 studies|Cross-sectional case-control design prevents causal conclusions. Controls were from a general population survey while cases were suicide decedents, creating potential selection bias. Mental health con

Survey of 1,113 Polish adults found 81% support medical cannabis and 84% would try it, but only 4

Moderate Evidence
10 studies|Online survey may underrepresent older adults and rural populations despite nationally representative sampling. Self-reported attitudes may not reflect behavior. Cross-sectional design captures one ti

Analysis of 496 cannabis users in São Paulo identified four distinct profiles, with about 30% in high-risk categories characterized by early onset, frequent use, and polydrug patterns

Moderate Evidence
10 studies|Cross-sectional design limits causal inference. Self-reported substance use. São Paulo sample may not represent all of Brazil. Latent class analysis findings are sample-dependent and may not replicate

Study of 95,645 Northern California teens found cannabis retail bans associated with lower psychotic disorder rates, and greater retail density linked to higher rates of anxiety and depressive disorders

Moderate Evidence
10 studies|Cross-sectional design cannot establish causation. Cannabis use itself was not measured, only retail availability and mental health outcomes. Residual confounding by neighborhood socioeconomic factors

What We Still Don't Know

  • Only 0 randomized controlled trials exist out of 38 studies — most evidence is observational or from reviews.
  • No meta-analyses have been published on this specific topic, limiting the ability to draw pooled quantitative conclusions.
  • Sex-specific differences in this area remain understudied.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Observational & Cohort(Tier 3-4)
29 (76%)
Reviews & Scoping(Tier 4)
1 (3%)
Other
8 (21%)

Key Studies

The most impactful research in this area.

Teen Cannabis Use Has Dropped Since 1999 — But Girls Now Use More Than Boys

The historic gender reversal challenges decades of assumptions about male-predominant cannabis use and demands updated prevention approaches that address why girls are now using more.

2026

The Legal Loophole That Put THC Drinks in Every State — Including Where Marijuana Is Illegal

Intoxicating THC beverages are now legally sold in states that specifically chose to ban marijuana — exploiting a federal loophole that lawmakers didn't anticipate when legalizing agricultural hemp.

2026

Living Near a Cannabis Store Linked to 12% More Cannabis ER Visits

This is among the strongest evidence that cannabis retail density directly affects health harms. It suggests policymakers can reduce cannabis-related ER visits by limiting store density or prohibiting stores in certain areas — a practical, implementable public health tool.

2026

7% of Adolescents Worldwide Used Cannabis, With Boys and the Americas Leading Rates

This is one of the most comprehensive global assessments of adolescent cannabis use, filling a critical gap in data from low- and middle-income countries that have been underrepresented in previous research.

2025

Cannabis Treatment Demand Nearly Tripled in Germany Over 20 Years, With Patients Getting Older

With Germany legalizing cannabis in 2024, understanding pre-legalization treatment demand trends is essential for planning services. The aging treatment population suggests current programs designed for young users may be inadequate.

2025

Most Teens Heard About the Vaping Lung Injury Outbreak — But Most Blamed Nicotine, Not Cannabis

The EVALI crisis killed 68 people, primarily from vitamin E acetate in illicit cannabis vapes. But the public health message was garbled — most teens think nicotine vapes were the problem. This misinformation may cause teens to avoid less-harmful nicotine vapes while underestimating risks of illicit

2025

Research Timeline

How our understanding of this topic has evolved.

2020–present

38 studies published. Includes 6 strong-evidence studies.

About This Consensus

This consensus synthesizes 38 peer-reviewed studies: 29 observational studies (76%), 1 reviews (3%), 8 other study types (21%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 38 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.